Caribou Biosciences (NASDAQ:CRBU – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01, Zacks reports. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.
Caribou Biosciences Price Performance
NASDAQ:CRBU opened at $1.07 on Wednesday. Caribou Biosciences has a one year low of $1.01 and a one year high of $7.24. The company has a market cap of $96.89 million, a P/E ratio of -0.65 and a beta of 2.34. The firm’s fifty day moving average price is $1.41 and its two-hundred day moving average price is $1.80.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on CRBU shares. Citigroup cut their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $10.33.
About Caribou Biosciences
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Caribou Biosciences
- What does consumer price index measure?
- 3 Companies Buying Back Stock—Why It Matters
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Institutions Bought 3 Stocks Heavily in Q1 2025
- How Can Investors Benefit From After-Hours Trading
- Beyond a Market Correction, Moves to Make Now
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
